Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17


Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease.

Caron NS, Southwell AL, Brouwers CC, Cengio LD, Xie Y, Black HF, Anderson LM, Ko S, Zhu X, van Deventer SJ, Evers MM, Konstantinova P, Hayden MR.

Nucleic Acids Res. 2020 Jan 10;48(1):36-54. doi: 10.1093/nar/gkz976.


A Comprehensive Haplotype-Targeting Strategy for Allele-Specific HTT Suppression in Huntington Disease.

Kay C, Collins JA, Caron NS, Agostinho LA, Findlay-Black H, Casal L, Sumathipala D, Dissanayake VHW, Cornejo-Olivas M, Baine F, Krause A, Greenberg JL, Paiva CLA, Squitieri F, Hayden MR.

Am J Hum Genet. 2019 Dec 5;105(6):1112-1125. doi: 10.1016/j.ajhg.2019.10.011. Epub 2019 Nov 7.


Activation of Caspase-6 Is Promoted by a Mutant Huntingtin Fragment and Blocked by an Allosteric Inhibitor Compound.

Ehrnhoefer DE, Skotte NH, Reinshagen J, Qiu X, Windshügel B, Jaishankar P, Ladha S, Petina O, Khankischpur M, Nguyen YTN, Caron NS, Razeto A, Meyer Zu Rheda M, Deng Y, Huynh KT, Wittig I, Gribbon P, Renslo AR, Geffken D, Gul S, Hayden MR.

Cell Chem Biol. 2019 Sep 19;26(9):1295-1305.e6. doi: 10.1016/j.chembiol.2019.07.001. Epub 2019 Jul 25.


Intrinsic mutant HTT-mediated defects in oligodendroglia cause myelination deficits and behavioral abnormalities in Huntington disease.

Ferrari Bardile C, Garcia-Miralles M, Caron NS, Rayan NA, Langley SR, Harmston N, Rondelli AM, Teo RTY, Waltl S, Anderson LM, Bae HG, Jung S, Williams A, Prabhakar S, Petretto E, Hayden MR, Pouladi MA.

Proc Natl Acad Sci U S A. 2019 May 7;116(19):9622-9627. doi: 10.1073/pnas.1818042116. Epub 2019 Apr 23.


Huntingtin suppression restores cognitive function in a mouse model of Huntington's disease.

Southwell AL, Kordasiewicz HB, Langbehn D, Skotte NH, Parsons MP, Villanueva EB, Caron NS, Østergaard ME, Anderson LM, Xie Y, Cengio LD, Findlay-Black H, Doty CN, Fitsimmons B, Swayze EE, Seth PP, Raymond LA, Frank Bennett C, Hayden MR.

Sci Transl Med. 2018 Oct 3;10(461). pii: eaar3959. doi: 10.1126/scitranslmed.aar3959.


Therapeutic approaches to Huntington disease: from the bench to the clinic.

Caron NS, Dorsey ER, Hayden MR.

Nat Rev Drug Discov. 2018 Oct;17(10):729-750. doi: 10.1038/nrd.2018.133. Epub 2018 Sep 21. Review.


Huntington Disease.

Caron NS, Wright GEB, Hayden MR.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2020.
1998 Oct 23 [updated 2018 Jul 5].


Constitutive ablation of caspase-6 reduces the inflammatory response and behavioural changes caused by peripheral pro-inflammatory stimuli.

Ladha S, Qiu X, Casal L, Caron NS, Ehrnhoefer DE, Hayden MR.

Cell Death Discov. 2018 Mar 12;4:40. doi: 10.1038/s41420-018-0043-8. eCollection 2018.


Preventing mutant huntingtin proteolysis and intermittent fasting promote autophagy in models of Huntington disease.

Ehrnhoefer DE, Martin DDO, Schmidt ME, Qiu X, Ladha S, Caron NS, Skotte NH, Nguyen YTN, Vaid K, Southwell AL, Engemann S, Franciosi S, Hayden MR.

Acta Neuropathol Commun. 2018 Mar 6;6(1):16. doi: 10.1186/s40478-018-0518-0.


Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease.

Garcia-Miralles M, Hong X, Tan LJ, Caron NS, Huang Y, To XV, Lin RY, Franciosi S, Papapetropoulos S, Hayardeny L, Hayden MR, Chuang KH, Pouladi MA.

Sci Rep. 2016 Aug 16;6:31652. doi: 10.1038/srep31652.


Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons.

Ehrnhoefer DE, Caron NS, Deng Y, Qiu X, Tsang M, Hayden MR.

Exp Neurol. 2016 Sep;283(Pt A):121-8. doi: 10.1016/j.expneurol.2016.06.008. Epub 2016 Jun 11.


Huntingtin Haplotypes Provide Prioritized Target Panels for Allele-specific Silencing in Huntington Disease Patients of European Ancestry.

Kay C, Collins JA, Skotte NH, Southwell AL, Warby SC, Caron NS, Doty CN, Nguyen B, Griguoli A, Ross CJ, Squitieri F, Hayden MR.

Mol Ther. 2015 Nov;23(11):1759-1771. doi: 10.1038/mt.2015.128. Epub 2015 Jul 23.


Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression.

Southwell AL, Smith SE, Davis TR, Caron NS, Villanueva EB, Xie Y, Collins JA, Ye ML, Sturrock A, Leavitt BR, Schrum AG, Hayden MR.

Sci Rep. 2015 Jul 15;5:12166. doi: 10.1038/srep12166.


Establishing cancer risks associated with PMS2 germline mutations in Lynch syndrome.

Caron NS.

Clin Genet. 2015 Jun;87(6):533-4. doi: 10.1111/cge.12583. Epub 2015 Apr 6. No abstract available.


Live cell imaging and biophotonic methods reveal two types of mutant huntingtin inclusions.

Caron NS, Hung CL, Atwal RS, Truant R.

Hum Mol Genet. 2014 May 1;23(9):2324-38. doi: 10.1093/hmg/ddt625. Epub 2013 Dec 11.


Polyglutamine domain flexibility mediates the proximity between flanking sequences in huntingtin.

Caron NS, Desmond CR, Xia J, Truant R.

Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14610-5. doi: 10.1073/pnas.1301342110. Epub 2013 Jul 29.


Using FLIM-FRET to measure conformational changes of transglutaminase type 2 in live cells.

Caron NS, Munsie LN, Keillor JW, Truant R.

PLoS One. 2012;7(8):e44159. doi: 10.1371/journal.pone.0044159. Epub 2012 Aug 31.

Supplemental Content

Loading ...
Support Center